Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these findings may inform clinical decision-making in the second-line setting, following endocrine therapy plus CDK4/6 inhibitor therapy, for patients with ESR1-mutated tumors.
More Videos in Metastatic Breast Cancer Content Hub
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Polly Niravath, MD, breast oncologist, Houston Methodist Cancer Center, Texas, discusses breast to brain metastasis. Dr Nirvath also reviews some available medications to treat brain metastases in patients…
Approximately 30% of women with early-stage breast cancer will face metastatic disease, and 6% are diagnosed with metastatic breast cancer initially. Living with metastatic breast cancer can elicit…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Part 3 – Case Discussion & Wrap-up Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and…
Angela Belcher, PhD; Sangeeta Bhatia, MD, PhD; and Paula Hammond, PhD, from the Koch Institute at MIT, Cambridge, MA, present multi-dimensional approaches to early detection in ovarian cancer.…
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity…
In this video, Frédérique Penault-Llorca, MD, PhD, professor of pathology, University of Clermont-Ferrandand, France, and Aditya Bardia, MD, MPH, director of translational research integration, UCLA, discuss the current…
